210 related articles for article (PubMed ID: 25164771)
1. Targeted radionuclide therapy with RAFT-RGD radiolabelled with (90)Y or (177)Lu in a mouse model of αvβ3-expressing tumours.
Bozon-Petitprin A; Bacot S; Gauchez AS; Ahmadi M; Bourre JC; Marti-Batlle D; Perret P; Broisat A; Riou LM; Claron M; Boturyn D; Fagret D; Ghezzi C; Vuillez JP
Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):252-63. PubMed ID: 25164771
[TBL] [Abstract][Full Text] [Related]
2. In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD.
Sancey L; Ardisson V; Riou LM; Ahmadi M; Marti-Batlle D; Boturyn D; Dumy P; Fagret D; Ghezzi C; Vuillez JP
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2037-47. PubMed ID: 17674000
[TBL] [Abstract][Full Text] [Related]
3. αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4.
Jin ZH; Furukawa T; Degardin M; Sugyo A; Tsuji AB; Yamasaki T; Kawamura K; Fujibayashi Y; Zhang MR; Boturyn D; Dumy P; Saga T
Mol Cancer Ther; 2016 Sep; 15(9):2076-85. PubMed ID: 27422811
[TBL] [Abstract][Full Text] [Related]
4. 67Cu-Radiolabeling of a multimeric RGD peptide for αVβ3 integrin-targeted radionuclide therapy: stability, therapeutic efficacy, and safety studies in mice.
Jin ZH; Furukawa T; Ohya T; Degardin M; Sugyo A; Tsuji AB; Fujibayashi Y; Zhang MR; Higashi T; Boturyn D; Dumy P; Saga T
Nucl Med Commun; 2017 Apr; 38(4):347-355. PubMed ID: 28291159
[TBL] [Abstract][Full Text] [Related]
5. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effect of integrin targeted (177)Lu-3PRGD2 and combined therapy with Endostar.
Shi J; Fan D; Dong C; Liu H; Jia B; Zhao H; Jin X; Liu Z; Li F; Wang F
Theranostics; 2014; 4(3):256-66. PubMed ID: 24505234
[TBL] [Abstract][Full Text] [Related]
7. Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin αvβ3 targeting using single photon emission computed tomography and optical imaging.
Briat A; Wenk CH; Ahmadi M; Claron M; Boturyn D; Josserand V; Dumy P; Fagret D; Coll JL; Ghezzi C; Sancey L; Vuillez JP
Cancer Sci; 2012 Jun; 103(6):1105-10. PubMed ID: 22448775
[TBL] [Abstract][Full Text] [Related]
8. Two ⁹⁰Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy.
Liu Z; Shi J; Jia B; Yu Z; Liu Y; Zhao H; Li F; Tian J; Chen X; Liu S; Wang F
Mol Pharm; 2011 Apr; 8(2):591-9. PubMed ID: 21247151
[TBL] [Abstract][Full Text] [Related]
9. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
11. Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate.
Müller C; Reber J; Haller S; Dorrer H; Bernhardt P; Zhernosekov K; Türler A; Schibli R
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):476-85. PubMed ID: 24100768
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of a new bifunctional NETA chelate for molecular targeted radiotherapy using(90)Y or(177)Lu.
Kang CS; Chen Y; Lee H; Liu D; Sun X; Kweon J; Lewis MR; Chong HS
Nucl Med Biol; 2015 Mar; 42(3):242-9. PubMed ID: 25487552
[TBL] [Abstract][Full Text] [Related]
13. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
15. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
16. Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide.
Sancey L; Lucie S; Garanger E; Elisabeth G; Foillard S; Stéphanie F; Schoehn G; Guy S; Hurbin A; Amandine H; Albiges-Rizo C; Corinne AR; Boturyn D; Didier B; Souchier C; Catherine S; Grichine A; Alexeï G; Dumy P; Pascal D; Coll JL; Jean-Luc C
Mol Ther; 2009 May; 17(5):837-43. PubMed ID: 19259068
[TBL] [Abstract][Full Text] [Related]
17. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
Chakraborty S; Sarma HD; Vimalnath KV; Pillai MR
Nucl Med Biol; 2013 Oct; 40(7):946-54. PubMed ID: 23850487
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.
Chakraborty S; Shi J; Kim YS; Zhou Y; Jia B; Wang F; Liu S
Bioconjug Chem; 2010 May; 21(5):969-78. PubMed ID: 20387808
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
